Toshiyuki Seki

Dr. Toshiyuki Seki


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
NHNina Hartrampf
Nina Hartrampf
TSToshiyuki Seki
Toshiyuki Seki
ABAndreas Baumann
Andreas Baumann
PWPhilip Watson
Philip Watson
NVNynke A. Vepřek
Nynke A. Vepřek
DTDirk Trauner
Dirk Trauner

12 March 2023 in Cancers
Verified
Journal Article
Open access
PDF file
TSToshiyuki Seki
Toshiyuki Seki
AKAtsumi Kojima
Atsumi Kojima
SOShinichi Okame
Shinichi Okame
SYSatoshi Yamaguchi
Satoshi Yamaguchi
AOAikou Okamoto
Aikou Okamoto
KTKazuhiro Takehara
Kazuhiro Takehara
The revised World Health Organization classification of cervical cancer divides adenocarcinomas into human papillomavirus-associated (HPVa) and -independent (HPVi) types; the HPVi type is represented by the gastric type. The treatment outcomes of locally advanced adenocarcinoma (LaAC), based on this classification, are understudied. We investigated the outcomes of patients with HPVa and HPVi LaACs. Data for all consecutive patients with stage IB3 to IIIC1 adenocarcinoma who received treatment at 12 institutions throughout Japan between 2004 and 2009 were retrieved to analyze progression-free and overall survival. Central pathological review classified 103 and 48 patients as having HPVa and HPVi tumors, respectively. Usual- (84%) and gastric- (90%) type adenocarcinomas were the most frequent subtypes. Surgery was the primary treatment strategy for most patients. Progression-free and overall survival of patients with HPVi were worse than those of patients with HPVa (p = 0.009 and 0.032, respectively). Subgroup analysis by stage showed that progression-free survival was significantly different for stage IIB. The current surgical treatment strategy for LaACs is less effective for HPVi tumors than for HPVa tumors, especially those in stage IIB.

1 February 2017 in Gynecology and Minimally Invasive Therapy
Verified
Journal Article
Open access
TSToshiyuki Seki
Toshiyuki Seki
YHYoshinobu Hamada
Yoshinobu Hamada
TITeppei Ichikawa
Teppei Ichikawa
SOShin Onota
Shin Onota
MNManabu Nakata
Manabu Nakata
STSatoshi Takakura
Satoshi Takakura
A uterine artery pseudoaneurysm (UAP) can occur after a traumatic event to the uterus, and cause massive bleeding. A uterine manipulator has been widely used for gynecologic laparoscopic surgery as basically an atraumatic instrument. We describe here a woman with a UAP caused by a uterine manipulator. She underwent laparoscopic ovarian cystectomy with a uterine manipulator due to torsion of a left ovarian cyst. Eleven days later, she came to our hospital with massive vaginal bleeding. Transvaginal Color Doppler ultrasound showed an intrauterine cystic mass with swirling blood flow, and three-dimensional arterial imaging from computed tomography revealed a UAP on the left side. Selective uterine artery angiography demonstrated a pseudoaneurysm in the distal portion of the left uterine artery, and embolization was performed successfully. A UAP should be taken into consideration in uterine bleeding after the use of a uterine manipulator.

1 January 2025 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
STShinichi Tate
Shinichi Tate
TSToshiyuki Seki
Toshiyuki Seki
KNKyoko Nishikimi
Kyoko Nishikimi
YUYouichi Unno
Youichi Unno
MIMizue Itoi
Mizue Itoi
MSMakio Shozu
Makio Shozu
Tate S, et al. J Gynecol Oncol. 2025 Mar;36:e80. https://doi.org/10.3802/jgo.2025.36.e80

7 June 2022 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
SOSuguru Odajima
Suguru Odajima
TSToshiyuki Seki
Toshiyuki Seki
SKSayako Kato
Sayako Kato
KTKeisuke Tomita
Keisuke Tomita
YSYuichi Shoburu
Yuichi Shoburu
AOAikou Okamoto
Aikou Okamoto
Odajima S, et al. J Gynecol Oncol. 2022 Jun;33:e62. https://doi.org/10.3802/jgo.2022.33.e62

18 July 2024 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
NTNobutaka Takahashi
Nobutaka Takahashi
TSToshiyuki Seki
Toshiyuki Seki
KSKeita Sasaki
Keita Sasaki
RMRyunosuke Machida
Ryunosuke Machida
MIMitsuya Ishikawa
Mitsuya Ishikawa
TSToyomi Sato
Toyomi Sato
Background: The prognosis of gynecological malignancies has improved with the recent advent of molecularly targeted drugs and immune checkpoint inhibitors. However, these drugs are expensive and contribute to the increasing costs of medical care. Methods: The Japanese Clinical Oncology Group (JCOG) Health Economics Committee conducted a questionnaire survey of JCOG-affiliated facilities from July 2021 to June 2022 to assess the prevalence of high-cost regimens. Results: A total of 57 affiliated facilities were surveyed regarding standard regimens for advanced ovarian and cervical cancers for gynecological malignancies. Responses were obtained from 39 facilities (68.4%) regarding ovarian cancer and 37 (64.9%) concerning cervical cancer, with respective case counts of 854 and 163. For ovarian cancer, 505 of 854 patients (59.1%) were treated with regimens that included PARP inhibitors, costing >500 000 Japanese yen monthly, while 111 patients (13.0%) received treatments that included bevacizumab, with costs exceeding 200 000 Japanese yen monthly. These costs are ~20 and ~10 times higher than those of the conventional regimens, respectively. For cervical cancer, 79 patients (48.4%) were treated with bevacizumab regimens costing >200 000 Japanese yen per month, ~10 times the cost of conventional treatments. Conclusions: In this survey, >70% of patients with ovarian cancer were treated with regimens that included poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors or bevacizumab; ~50% of patients with cervical cancer were treated with regimens containing bevacizumab. These treatments were ~10 and ~20 times more expensive than conventional regimens, respectively. These findings can inform future health economics studies, particularly in assessing cost-effectiveness and related matters.